2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
- Home
- Clinical Resources Search
- Overview of BTCEs: Engaging with Bispecific T-Cell Engagers
Engaging with Bispecific T-Cell Engagers
Last Updated: November 20, 2025
An overview of how these agents’ function, their dosing schedules, notable side effects, and the Risk Evaluation and Mitigation Strategies (REMS) requirements for certain agents.
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Up Close with Linvoseltamab
Last Updated: 06/29/2026
Overview of BTCEs: Comparison of Bispecific T-Cell Engagers (BTCEs)
Last Updated: 04/23/2026
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 07/01/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 07/01/2025
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Patient Education Sheet
Immune Globulin
Last Updated: 08/18/2026
Docetaxel and Gemcitabine
Last Updated: 08/18/2026
Durvalumab and Bacillus Calmette-Guérin
Last Updated: 08/18/2026
Mitomycin Given into the Bladder
Last Updated: 08/18/2026